Multidisciplinary Management of Early-Stage Rectal Cancer

Because patients with locally advanced rectal cancer are at high risk for both recurrence and distant disease, they require adjuvant therapy. In the United States, the current standard of care is neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Neoadjuvant chemoradiation has been shown to improve local recurrence rates and decrease toxicity. However in the era of total mesorectal excision surgery, no study has shown a survival benefit to either chemoradiation or postoperative chemotherapy. Newer biologic therapies, although promising in initial early trials, have yet to show a significant benefit in adjuvant therapy for rectal cancer.

Target Audience

This activity has been designed to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the current standard of care for the management of patients with rectal cancer
  • Discuss the role of adjuvant therapy in the management of rectal cancer
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
12/01/2012
Course expires: 
12/01/2013
Cost:
$0.00

John G. Phillips, MD
Harvard Radiation Oncology Program
Harvard Medical School
Boston, Massachusetts

Theodore S. Hong, MD
Department of Radiation Oncology
Massachusetts General Hospital
Boston, Massachusetts

David P. Ryan, MD
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Accreditation Period

Course opens: 
12/01/2012
Course expires: 
12/01/2013

Price

Cost:
$0.00
Please login or register to take this course.